Oncorus Inc - ESG Rating & Company Profile powered by AI
The ESG score covers seventeen UN Sustainable Development Goals including: 'Gender Equality', 'Responsible Production & Consumption' and 'Life on Land'. This webpage contains a free E,S&G assessment covering Oncorus Inc. Alternative companies in the rating peer group for Oncorus Inc are shown below.
Oncorus Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.5; made up of an environmental score of 0.0, social score of 0.0 and governance score of 1.6.
0.5
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1898 | Zota Health Care Ltd | 0.7 | Low |
| 1898 | cbdMD Inc | 0.7 | Low |
| 1924 | Oncorus Inc | 0.5 | Low |
| 1924 | Beximco Pharmaceuticals Ltd | 0.5 | Low |
| 1924 | Acucela Inc | 0.5 | Low |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Oncorus Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Oncorus Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Oncorus Inc report the average age of the workforce?
Sign up for free to unlockDoes Oncorus Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Oncorus Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Oncorus Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Oncorus Inc offer flexible work?
Sign up for free to unlockDoes Oncorus Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Oncorus Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Oncorus Inc conduct supply chain audits?
Sign up for free to unlockDoes Oncorus Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Oncorus Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Oncorus Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Oncorus Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Oncorus Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Oncorus Inc disclose water use targets?
Sign up for free to unlockDoes Oncorus Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Oncorus Inc have a product recall in the last two years?
Sign up for free to unlockDoes Oncorus Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Oncorus Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Oncorus Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Oncorus Inc disclose parental leave metrics?
Sign up for free to unlockDoes Oncorus Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Oncorus Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Oncorus Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Oncorus Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Oncorus Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Oncorus Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Oncorus Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Oncorus Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Oncorus Inc disclose its waste policy?
Sign up for free to unlockDoes Oncorus Inc report according to TCFD requirements?
Sign up for free to unlockDoes Oncorus Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Oncorus Inc disclose energy use targets?
Sign up for free to unlockDoes Oncorus Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Oncorus Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Oncorus Inc
These potential risks are based on the size, segment and geographies of the company.
Oncorus, Inc., a clinical stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. Oncorus, Inc. has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.